Latest news with #Cipla
Time of India
4 hours ago
- Business
- Time of India
Cipla Share Price Live Updates: Cipla's One-Week Returns Reflect a -1.07% Change
17 Jul 2025 | 09:23:59 AM IST Discover the Cipla Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent stock. Keep track of Cipla with the latest details, including: Last traded price 1480.7, Market capitalization: 119188.13, Volume: 50814, Price-to-earnings ratio 22.61, Earnings per share 65.28. Our comprehensive coverage combines fundamental and technical indicators to provide you with a comprehensive view of Cipla's performance. Stay informed about breaking news that can sway Cipla's trajectory in the market. With our expert insights and stock recommendations, make well-informed financial decisions. Join us on this journey as we explore the exciting potential of Cipla. The data points are updated as on 09:23:59 AM IST, 17 Jul 2025 Show more
Time of India
a day ago
- Business
- Time of India
Cipla Share Price Live Updates: Cipla's Monthly Return Overview
Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ahead of the market with our in-depth coverage of Cipla, including: Last traded price 1485.0, Market capitalization: 120407.64, Volume: 2669, Price-to-earnings ratio 22.84, Earnings per share 65.28. Get a complete picture of Cipla's performance through our comprehensive blend of fundamental and technical indicators. Stay informed about breaking news that can influence the stock's trajectory. Our liveblog equips you with the knowledge and insights needed to make confident investment decisions. Don't miss out on the latest updates as Cipla continues to make waves in the market. The data points are updated as on 09:12:19 AM IST, 16 Jul 2025 Show more Show less
The Hindu
2 days ago
- Health
- The Hindu
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug
Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused on HIV medicines and majority owned by GSK with Pfizer and Shionogi as shareholders, and Medicines Patent Pool (MPP) extending their voluntary licensing agreement to enable access to long-acting injectable HIV treatment. It builds on the voluntary license for CAB LA for HIV pre-exposure prophylaxis (PrEP). The announcement, on extending their agreement, comes in the wake of an updated guidance from World Health Organization (WHO) recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option. Existing licensees Aurobindo, Cipla and Viatris will consequently be able to develop, manufacture and supply generic versions of CAB LA, for use in combination with long-acting rilpivirine, for the treatment of HIV-1 infection in adults and adolescents weighing at least 35kg subject to required regulatory approvals being obtained, Aurobindo Pharma said on Tuesday. Vice chairman and MD of Aurobindo Pharma K. Nithyananda Reddy said the company remains committed to leveraging its global supply capabilities to make the vital combination long-acting injection therapy widely available and affordable. The consideration by ViiV and MPP to include the private market in royalty-bearing countries is a critical step toward expanding access across both public and private sectors, he said.
Time of India
3 days ago
- Business
- Time of India
Cipla Share Price Live Updates: Cipla's Recent 3-Month Returns
14 Jul 2025 | 09:03:00 AM IST Stay informed with the Cipla Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a leading stock. Get the latest details on Cipla, including: Last traded price 1486.0, Market capitalization: 119931.14, Volume: 1244, Price-to-earnings ratio 22.75, Earnings per share 65.28. Our liveblog combines fundamental and technical insights to provide a holistic view of Cipla's performance. Stay ahead of the market with breaking news that can influence Cipla's trajectory. Our expert analysis and stock recommendations empower you to make well-informed financial decisions. Trust the Cipla Stock Liveblog for up-to-date information and expert insights. The data points are updated as on 09:03:00 AM IST, 14 Jul 2025 Show more
Time of India
3 days ago
- Business
- Time of India
Cipla eyes weight management foray: CEO
Representative image NEW DELHI: Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra said in the company's annual report for FY25. The Mumbai-based company is also strengthening its presence in the central nervous system therapeutic area, he said. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
